|1.4396 -0.94 (-39.51%)||11-29 11:14|
|Targets||6-month :||2.18||1-year :||3.46|
|Resists||First :||1.87||Second :||2.97|
|Supports||First :||0.1||Second :||0.08|
|MAs||MA(5) :||0.84||MA(20) :||0.32|
|MA(100) :||0.74||MA(250) :||0.81|
|MACD||MACD :||0.2||Signal :||0|
|%K %D||K(14,3) :||43.3||D(3) :||38.2|
|52-week||High :||2.97||Low :||0.1|
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ SEEL ] has closed below upper band by 7.2%. Bollinger Bands are 452.7% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 1 days. This is a sign that the current trend might continue.
|If tomorrow:||Open lower||Open higher|
|High:||2.97 - 2.99||2.99 - 3|
|Low:||2.21 - 2.22||2.22 - 2.23|
|Close:||2.36 - 2.38||2.38 - 2.4|
Seelos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of central nervous system, respiratory, and other disorders. The company's lead programs are SLS-002, an intranasal racemic ketamine for the treatment of acute suicidal ideation and behavior in patients with major depressive disorders; SLS-005, a protein stabilizer for the treatment of amyotrophic lateral sclerosis and Sanfilippo syndrome; and SLS-006, a partial dopamine agonist for the treatment of patients with Parkinson's disease (PD). Its preclinical programs include SLS-007, an anti-alpha-synuclein peptidic inhibitor to treat patients with PD; SLS-008, an orally available antagonist for chemoattractant receptor-homologous molecule for the treatment of chronic inflammation in asthma and pediatric orphan indications; SLS-004 for the treatment of PD; SLS-010, an oral histamine H3A receptor antagonist for narcolepsy and related disorders; and SLS-012, an injectable therapy for post-operative pain management. Seelos Therapeutics, Inc. was incorporated in 1987 and is headquartered in New York, New York.
|Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
|Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
|Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
|Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
|Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
|Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
|Shares Out||0 (M)|
|Shares Float||161 (M)|
|Held by Insiders||1.4615e+008 (%)|
|Held by Institutions||2.8 (%)|
|Shares Short||10,230 (K)|
|Shares Short P.Month||0 (K)|
|EPS Est Next Qtrly||0|
|EPS Est This Year||0|
|EPS Est Next Year||0|
|Book Value (p.s.)||0|
|Profit Margin||0 %|
|Operating Margin||-3 %|
|Return on Assets (ttm)||104.1 %|
|Return on Equity (ttm)||-135.8 %|
|Qtrly Rev. Growth||1.55e+006 %|
|Gross Profit (p.s.)||0|
|Sales Per Share||0|
|Qtrly Earnings Growth||-0.5 %|
|Operating Cash Flow||0 (M)|
|Levered Free Cash Flow||-35 (M)|
|Price to Book value||0|
|Price to Sales||0|
|Price to Cash Flow||-17.7|
|Dividend Pay Date||Invalid DateTime.|
|Ex-Dividend Date||Invalid DateTime.|